ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Cooperative Group Consolidation Unlikely To Save Money, NCI’s Doroshow Says

September 24, 2010

Appropriators Ask What Happens After NIH Budget-Doubling Ends In FY2004.

May 25, 2001

In Brief: NCI Funded To Dec. 15, No Senate Figure Yet; Speedup Urged On Interferon Manufacturing, Testing

October 10, 1980

Breast, Ovarian Cancers Detected Early In Women At High Hereditary Risk

March 29, 2002

In Brief: Carcinogenesis: Does The Promise Justify The Effort? Task Force Attempts To Find Out

September 30, 1977

DCE Board Delays Decision On New Collaborative Groups In Chemoprevention

November 30, 1984